Clearmind Medicine Announces Promising Results in Obesity Treatment from Pre-Clinical Trial

Clearmind Medicine Inc. a biotech company at the forefront of developing novel psychedelic-derived therapeutics, has announced encouraging outcomes from its latest pre-clinical trial. The study, spearheaded by Professor Joseph Tam of The Hebrew University of Jerusalem, explored the efficacy of a groundbreaking treatment combination for obesity, metabolic disorders, and depression.

This innovative trial utilized Clearmind’s proprietary psychedelic treatment, MEAI, known for its potential in treating various addictions, obesity, and metabolic disorders, alongside SciSparc’s Palmitoylethanolamide (PEA), an anti-inflammatory agent and the active ingredient in SciSparc’s CannAmide™. The primary objective was to ascertain the optimal dosage for this combination and to evaluate its impact on key metabolic and behavioral parameters such as fat oxidation, locomotor activity, and feeding behavior.

The trial involved 14 distinct treatment groups with a total of 84 animals, receiving varying single treatment doses of MEAI (ranging from 40 to 0.5 mg/kg) with or without a consistent PEA dose of 25 mg/kg. The results were remarkable, demonstrating a high degree of tolerance to MEAI across all groups, with no adverse impact on the animals’ viability. Notably, the most significant effects were observed when combining MEAI and PEA, especially at 20 and 10 mg/kg dosages. These results indicated several key findings:

1. The combination treatment was well-tolerated, with no adverse effects on the mice’s viability across all groups.
2. The MEAI and PEA combination, particularly at 20 and 10 mg/kg, led to increased metabolic processes and fat oxidation, as evidenced by elevated oxygen consumption, carbon dioxide emission, and energy expenditure.
3. A substantial reduction in food consumption and meal sizes was noted, primarily at higher MEAI doses of 40 and 20 mg/kg.
4. There were slight increases in carbohydrate oxidation at the 20 and 10 mg/kg levels.
5. Significant reductions in ambulation were observed at 40 and 20 mg/kg, without impeding voluntary activity.

Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind, expressed enthusiasm over the results, emphasizing the potential of their proprietary MEAI-based treatment. This comes at a time when the demand for weight loss medications is increasing, despite concerns over severe side effects associated with current market options. Dr. Zuloff-Shani highlighted the safety profile and efficacy of MEAI, particularly in targeting fat loss while maintaining and enhancing energy levels, motivation, and other positive effects.

Professor Joseph Tam echoed these sentiments, noting the significant advancements the MEAI and PEA combination treatment represents in the development of safer and more effective therapies for weight management. The observed increase in metabolic processes and fat oxidation, coupled with reduced appetite, positions this treatment as a promising contender in the battle against obesity and metabolic disorders.